- Research Services
- Antibody Discovery
- Antibody and Protein Engineering
- Cell Line Development
- Development & Manufacturing
- Investor Relations
- Contact Us
In phage display technology, antibody fragments (Fabs) are fused to the filamentous bacteriophage M13 gene III coat proteins, thus allowing billions of phages to be produced that each display on their surface an antibody fragment with a unique specificity. These highly diverse phage populations can then be presented to the desired target and, through a process of selection, amplification and re-selection (panning), antibody fragments can be isolated that have high specificity for the antigen.
Due to the flexibility of the phage display-based selection process, this technology enables the identification of antibody fragments with very specific characteristics, representing an alternative to the classical hybridoma technology.
By reducing the concentration of antigen and the use of stringent conditions during panning, Fabs can be selected that have high affinity/potency and are stable. Selection for function, for example antagonism, agonism, internalization and epitope specificity are also possible.
This technology has been used in projects such as generating mAbs against different domains of llama IgG1 and generating capture and detection mAbs for cancer and heart biomarkers.
Working with Abzena
Abzena’s services are tailored for each project to ensure that the objectives are met or exceeded. Experienced project teams are assigned to each study focusing on progressing projects through to results in the minimum amount of time. Our clients widely regard us as professional and attentive partners who deliver quality results.
For more information or a quote for our antibody discovery services and technologies contact us.